Skip to main content

Save the Date: Symposium on Linking Disease Model Phenotypes to Human Conditions

By

Monarch is co-hosting a NIH Symposium titled “Linking Disease Model Phenotypes to Human Conditions” on September 10-11, 2015 at the Fishers Lane Auditorium, NIH, Rockville, MD. 

The purpose of the meeting is to convene a colloquium on the current status of Phenomics and its role in closing the gap that exists between biomedical research and clinical medical practice. The wealth of whole organism, cellular, and molecular data generated in the research laboratory must be translated into clinically relevant knowledge that enables the physician to make the best possible treatment decisions. Phenomics is gaining momentum due to the availability of the complete genomes for many organisms as well as higher throughput methods to genetically modify model organism genomes and observe and record phenotypes. Disease models comprise some of the most important tools of biomedical research. The efficacy of the use of disease models is based upon the principles of evolutionary conservation between species, including conservation of pathogenic disease mechanisms. The lack of alignment of phenotypes between model species and humans has been a historic impediment to understanding disease processes. Further progress depends upon integration of clinical, biological and genomic data and development of the tools for identification and analysis of specific and amendable disease-causing molecular phenotypes of various diseases.

Session Topics: 
  • Current status of the human clinical phenotype ontology and terminology, and associated data annotation and use
  • Cross-species phenotype analysis and ontology
  • Large scale high throughput analysis of disease model phenotyping data and annotation of gene function
  • Linking disease-relevant phenotypes with physiologically relevant molecular pathways and networks 
  • Clinical and experimental biology data integration, and the positioning of molecular phenotypes in the emerging field of precision medicine 
  • Resources for submission, representation, analysis, and sharing of phenotypic and genomic information, development of resource identification and tracking to improve reproducibility and the tracking of resource utilization and trends


Organizing Committee: Oleg Mirochnitchenko (ORIP/NIH, MD), Harold Watson (ORIP/NIH, MD), Melissa Haendel (Oregon Health & Science University, OR), Olga Troyanskaya (Princeton University, NJ), Olivier Bodenreider  (NIH Library, MD), Yves Lussier (University of Arizona, AZ), Phil Bourne  (DS/NIH, MD), Janan Eppig (The Jackson Laboratory, ME), Mary Mullins (University of Pennsylvania, PA).

Symposium program and registration to attend this event at:
http://www.scgcorp.com/linkingdisease2015/.

Please, register early, space is limited!

For more information on meeting logistics and registration, contact: Mark A. Dennis at mdennis@scgcorp.com,

P: (301) 670-4990, ext. 237
F: (301) 670-3815

For programmatic questions contact Oleg Mirochnitchenko at Oleg.Mirochnitchenko@nih.gov,
P: (301) 435-0748

Confirmed speakers include: 
Peter N. Robinson (Max Planck Institute for Molecular Genetics, Germany)
Carol M. Hamilton (PhenX, NC), Rachel Richesson (Duke University, NC)
Rex L. Chisholm (Northwestern University, IL)
Melissa Haendel (Oregon Health and Science University, OR)
Damian Smedley (Wellcome Trust Sanger Institute, UK)
Chris Mungall (Lawrence Berkeley Laboratory, CA)
Caleb Webber (Oxford University, UK)
Janan Eppig (The Jackson Laboratory, ME)
Elissa Chessler (The Jackson Laboratory, ME)
Derek Stemple (Welcome Trust Sanger Institute, UK)
Ross Cagan (The Mount Sinai Hospital, NY)
Olga Troyanskaya (Princeton University, NJ)
Kara Dolinski (Princeton University, NJ) 
John Quackenbush (Dana-Farber Cancer Institute, MA)
Jason Moore (Dartmouth College, NH)
Yves Lussier (Univ. of Arizona, AZ)
Razelle Kurzrock (Univertsity of California San Diego, CA)
Gail Herman (Nationwide Children's Hospital in Columbus, OH)
Calumn MacRae (Harvard Medical School and Brigham and Women's Hospital, MA)
Maryann Martone (University of California San Diego, CA)
Nicole Washington (Lawrence Berkeley National Laboratory, CA)
Paul Thomas (University of Southern California, CA)
Mary Mullins (University of Pennsylvania, PA)
Olivier Bodenreider (NIH Library, Bethesda, MD)
Phil Bourne (NIH, MD).  

Individuals with disabilities who need Sign Language Interpreters and/or reasonable accommodation to participate in this event should contact RegenerativeMedicine@lmbps.com or the Federal Relay (1-800-877-8339).


 This symposium is sponsored by the Office of Research Infrastructure Programs, DPCPSI/OD/NIH.

Popular posts from this blog

How to annotate a patient's phenotypic profile

By
How to annotate a patient's phenotypic profile using PhenoTips and the Human Phenotype Ontology Purpose We have observed that performance of computational search algorithms within and across species improves if a comprehensive list of phenotypic features is recorded. It is helpful if the person annotating thinks of the set of annotations as a query against all known phenotype profiles. Therefore, the set of phenotypes chosen for the annotation must be as specific as possible, and represent the most salient and important observable phenotypes. Towards this end, Monarch has been asked to provide guidance on how to create a quality patient profile using the Human Phenotype Ontology (HPO). Below we detail our annotation guidelines for use in the PhenoTips application, our partner organization.  The guidelines can also be considered more generically so as to be applicable to any annotation effort using HPO or even using other phenotype ontologies.  The annotations should b...
Read more

Why the Human Phenotype Ontology?

By
We've often been asked, why should we use the Human Phenotype Ontology to describe patient phenotypes, rather than a more widely-used clinical vocabulary such as ICD or SNOMED? Here are the answers to some of these frequently asked questions: 1. We should use what other big NIH projects, like ClinVar, are using. ClinVar is using HPO terms to describe phenotypes. This is done in collaboration with MedGen, which has imported HPO terms. Here is an example: http://www.ncbi.nlm.nih.gov/medgen/504827 There are now many bioinformatics tools that use the HPO to empower exome diagnostics. The Monarch team has published two of these recently 1) Exomiser ( Robinson et al., 2014 Genome Res. ) => For discovering new disease genes via model organism data, several successful use cases at UDP and elsewhere 2) PhenIX ( Zemojtel et al., 2014 Science Translational Medicine ) => For clinical diagnostics of “difficult” cases. This paper was on Russ Altman's year in review at AMIA this year. ...
Read more

Finally, a medical terminology that patients, doctors, and machines can all understand.

By
By Nicole Vasilevsky, Mark Engelstad, Erin Foster, Julie McMurry, Chris Mungall, Peter Robinson, Sebastian Köhler, Melissa Haendel For many patients with rare and undiagnosed diseases, getting an accurate diagnosis, or even finding the appropriate experts is a long and winding road. To accelerate and facilitate this process, we developed a medical vocabulary (“HPO”) which is comprised of 12,000 terms that doctors can use to codify the precise and distinct observations about patients and their conditions. The HPO is structured in a way that enables machines to intelligently compare a patient’s profile with what scientists worldwide have already uncovered about diseases and their genetic causes. Until now, most of the HPO labels and synonyms were composed of clinical terms unfamiliar to patients. For example, a patient may know they are ‘color-blind’, but may not be familiar with the clinical term ‘Dyschromatopsia’. This is why we developed a layer of 5,000 corresponding terms tha...
Read more